1. Introduction {#sec1-nutrients-11-01493}
===============

Obesity and the ensuing metabolic syndrome (MetS) are becoming an epidemic. If recent secular trends continue unabated, up to 20% of the world's adult population (1.2 billion individuals) is expected to be obese by 2030. The prevalence of type 2 diabetes mellitus (T2DM) and cardiovascular disease (CVD) are also expected to increase by 54% and 22%, respectively \[[@B1-nutrients-11-01493],[@B2-nutrients-11-01493],[@B3-nutrients-11-01493],[@B4-nutrients-11-01493]\].

In an effort to tackle the problem of obesity, and in turn cardiovascular risk, nutritional guidelines recommended a global limit on total fat intake, inevitably resulting in an increased intake of simple carbohydrates and decreased intake of healthy unsaturated fatty acids (UFA) \[[@B5-nutrients-11-01493]\]. Dietary UFA may prevent the development of metabolic diseases such as T2DM, and reduce cardiovascular events \[[@B6-nutrients-11-01493]\]. Moreover, the presumed relationship between dietary saturated fatty acids (SFA) and an increased risk of coronary heart disease (CHD) or CVD may depend on the complexity of these fatty acids and the food matrix in which they are present \[[@B7-nutrients-11-01493]\].

Evidence currently available resulting from the dietary fat interventions does not support the current dietary fat guidelines \[[@B8-nutrients-11-01493]\]. In 2015, the Dietary Guidelines Advisory Committee emphasized the importance of healthful, food-based diet patterns, revisiting the role of fat in health \[[@B9-nutrients-11-01493]\].

The Mediterranean diet (MedDiet) is characterized by high intakes of plant foods (fruits, vegetables, legumes, nuts, and whole grains) and olive oil as the principal source of dietary lipids \[[@B10-nutrients-11-01493]\]. This dietary pattern seems to ameliorate metabolic risk factors defining the MetS \[[@B11-nutrients-11-01493]\] (and reduce the incidence of cardiovascular events, breast cancer, and T2DM compared with any other diet \[[@B12-nutrients-11-01493],[@B13-nutrients-11-01493]\].

The PREvención con DIeta MEDiterránea (PREDIMED)-Plus study provides a unique opportunity to assess the association between fat intake and MetS components in an adult Mediterranean population at high CVD risk.

2. Methods {#sec2-nutrients-11-01493}
==========

2.1. Study Design {#sec2dot1-nutrients-11-01493}
-----------------

This research represents a cross-sectional study on baseline data of the PREDIMED-Plus trial. PREDIMED-Plus study is an ongoing 6-year multicenter, parallel-group, randomized trial conducted in 23 Spanish recruiting centers to evaluate the effect of an intensive weight loss program based on an energy-restricted traditional Mediterranean diet (erMedDiet), physical activity promotion, and behavioral support on hard cardiovascular events, in comparison with an usual care intervention only with energy-unrestricted MedDiet (control group) and any advice to increase physical activity. The PREDIMED-Plus study protocol is fully described in a publication by Martínez-González et al. \[[@B14-nutrients-11-01493]\] and available at <http://predimedplus.com/>. The trial was registered in 2014 at the International Standard Randomized Controlled Trial (ISRCT; <http://www.isrctn.com/ISRCTN89898870>) with number 89898870.

2.2. Participants, Recruitment, and Randomization {#sec2dot2-nutrients-11-01493}
-------------------------------------------------

Eligible participants were community-dwelling adults men aged between 55 and 75 years and women between 60 and 75 years, without documented history of CVD at enrollment, who were overweight or obese (body mass index \[BMI\] ≥27 and \<40 kg/m^2^) and meeting at least 3 criteria for the MetS according to the updated harmonized definition of the International Diabetes Federation and the American Heart Association and National Heart, Lung and Blood Institute \[[@B15-nutrients-11-01493]\]: Abdominal obesity for European individuals (WC ≥88 cm in women and ≥102 cm in men), hypertriglyceridemia (≥150 g/dL) or drug treatment for high plasma triglycerides (TG) concentrations, low high-density lipoprotein cholesterol (HDL-cholesterol; ≤50 mg/dL in women and ≤40 mg/dL in men), high blood pressure (systolic blood pressure ≥130 mmHg or diastolic blood pressure ≥85 mmHg or antihypertensive drug treatment), or high fasting plasma glucose (≥100 mg/dL) or drug treatment for T2DM.

From 5 September 2013 to 31 October 2016, a total of 6874 participants were recruited in 23 Spanish centers (universities, hospitals, and research institutes).

The present analysis included 6560 subjects (3387 men and 3173 women ([Figure 1](#nutrients-11-01493-f001){ref-type="fig"}) were included). We excluded those participants (*n* = 314) recording extreme total energy intakes (\<500 or \>3500 kcal/day in women or \<800 or \>4000 kcal/day in men) \[[@B16-nutrients-11-01493]\]. We also excluded participants who did not respond to all the physical activity questionnaires (*n* = 14) and participants reporting outliers for total physical activity expressed as metabolic equivalents of task \[METs·min/week (at 3 or more standard deviations \[SD\] from the mean for each sex)\].

2.3. Ethics {#sec2dot3-nutrients-11-01493}
-----------

All participants provided written informed consent, and the study protocol and procedures were approved according to the ethical standards of the Declaration of Helsinki by all the participating institutions.

2.4. Dietary Assessment {#sec2dot4-nutrients-11-01493}
-----------------------

Registered dietitians collected data on dietary intake at baseline with a semiquantitative 143-item food frequency questionnaire (FFQ), assessing dietary habits over the previous 12 months, repeatedly validated in Spain \[[@B17-nutrients-11-01493]\]. Detailed information about the development, reproducibility, and validity of FFQ in the PREDIMED cohort has been previously reported \[[@B17-nutrients-11-01493],[@B18-nutrients-11-01493],[@B19-nutrients-11-01493]\]. For each item, a typical portion size was included and consumption frequencies were registered in 9 categories that ranged from "never or almost never" to "≥6 times/day". Energy and nutrient intakes were calculated as frequency multiplied by nutrient composition of specified portion size for each food item, using a computer program based on available information in food composition tables \[[@B20-nutrients-11-01493],[@B21-nutrients-11-01493],[@B22-nutrients-11-01493],[@B23-nutrients-11-01493]\]. The selected frequency item was converted to a daily intake. For example, if a response was 5--6 times a week, it was converted to 0.78 servings per day (5.5 week/7 days) \[[@B19-nutrients-11-01493]\]. For each FFQ food item, we estimated the average amount of food consumed (grams), the average total energy intake, and the average intake of a set of macro-and micronutrients by computing the mean of the values for the individual foods assigned to that item \[[@B24-nutrients-11-01493]\].

We also considered the total nutrient intake, the average intake of micronutrients from dietary supplements declared by participants in the FFQ.

2.5. Determination of Fat Intake {#sec2dot5-nutrients-11-01493}
--------------------------------

Dietary intake of total fat and fatty acids: Monounsaturated (MUFA), polyunsaturated (PUFA), and saturated (SFA), trans-fatty acid (TFA), linoleic acid (LA), α-linolenic acid (ALA), and marine ω-3 fatty acid (ω-3 FA) were estimated.

On the other hand, the fat quality index (FQI) was calculated as previously described \[[@B16-nutrients-11-01493]\]. Briefly, the FQI was calculated using the ratio (MUFA + PUFA)/(SFA + TFA) as a continuous variable.

Participants were also administered a 17-item Mediterranean dietary questionnaire, a modified version of the previously validated questionnaire used in the PREDIMED trial \[[@B25-nutrients-11-01493]\]. Compliance with each of the 17 food habits reflecting an erMedDiet was scored with 1 point and 0 points otherwise. Therefore, a score ranging from 0--17 points, with 0 meaning no adherence and 17 meaning maximum adherence, was developed.

2.6. Physical Activity {#sec2dot6-nutrients-11-01493}
----------------------

Physical activity was measured using the Rapid Assessment of Physical Activity Questionnaires (RAPA-1 and RAPA-2) \[[@B26-nutrients-11-01493]\] and the validated Minnesota-REGICOR (Registre Gironí del Cor) Short Physical Activity questionnaire \[[@B27-nutrients-11-01493],[@B28-nutrients-11-01493],[@B29-nutrients-11-01493]\]. Metabolic Equivalent of tasks (MET) are calculated by multiplying the intensity (showed by the MET-score) and the duration spent on that activity (measured in minutes). The intensity was assigned based on the compendium of physical activity \[[@B30-nutrients-11-01493]\]. Detailed information about the development and reproducibility has been reported \[[@B31-nutrients-11-01493]\].

2.7. Anthropometric and Blood Pressure Measurements {#sec2dot7-nutrients-11-01493}
---------------------------------------------------

Anthropometric variables were measured by trained personnel according to the PREDIMED-Plus protocol. Weight and height were measured with high-quality electronic calibrated scales and a wall-mounted stadiometer, respectively. BMI was calculated as weight in kilograms divided by the square of height in meters. Waist circumference (WC) was measured halfway between the last rib and the iliac crest by using an anthropometric tape. Blood pressure was measured in triplicate with a validated semi-automatic oscillometer (Omron HEM-705CP) after 5 min of rest in-between measurements while the participant was in a seated position. All anthropometric variables were determined in duplicate, except for blood pressure (in triplicate).

2.8. Blood Collection and Analysis {#sec2dot8-nutrients-11-01493}
----------------------------------

Samples of fasting blood and urine were also collected after an overnight fast at baseline. Biochemical analyses were performed on fasting plasma glucose, total cholesterol, low high-density lipoprotein cholesterol (HDL-c,) and triglyceride (TG) concentrations in local laboratories using standard enzymatic methods.

2.9. Other Health Outcomes {#sec2dot9-nutrients-11-01493}
--------------------------

At the baseline visit, additional information related to sociodemographic and lifestyle aspects (education level, civil status, smoking habits, alcohol intake, physical activity, individual and family medical history, and current medication use) was collected.

2.10. Statistical Analyses {#sec2dot10-nutrients-11-01493}
--------------------------

Analyses were performed with the SPSS statistical software package version 25.0 (SPSS Inc., Chicago, IL, USA). We used the PREDIMED-Plus baseline database generated in August 2017. Overall, 8 nutrients were examined (total fat, MUFA, PUFA, SFA, TFA, LA, ALA and ω-3 FA). Following standard procedures, nutrient intakes were energy-adjusted using the residual method \[[@B32-nutrients-11-01493],[@B33-nutrients-11-01493]\] and then converted into quintiles. Qualitative variables were expressed as percentages and quantitative variables were expressed as means and SD. Pearson's chi-square tests and analysis of variance (ANOVA) (for categorical and continuous variables, respectively) were used to compare differences across quintile groups. We used the Bonferroni method to test multiple comparisons across quintile groups. Logistic regression analyses with the calculation of corresponding odds ratio (OR) and the 95% confidence interval (95% CI) were also used to assess the association between MetS components and quintiles of dietary fat and fat subtypes. Results were adjusted for sex, age (continuous variable), BMI (continuous variable), energy intake (continuous variable), alcohol intake (continuous variable), adherence to the MedDiet (continuous variables), total physical activity (continuous variable, expressed as MET·min/week), smoking habit (categorized variable: Current, former and never) and education level (categorized variable: Primary, secondary, university, or graduate) to control for potential confounders. Results were considered statistically significant if *p*-value (2 tailed) \<0.05.

3. Results {#sec3-nutrients-11-01493}
==========

The general characteristics of the study population across quintiles of total and several subtypes of dietary fat intake are shown in [Table 1](#nutrients-11-01493-t001){ref-type="table"}. The percentage of energy from total dietary fat of the participants ranged from 30.5 (SD: 2.9) in the lowest to 48.5 (SD: 3.3) in the highest quintile (mean: 39.4%, SD: 6.5). Specifically, women had significantly higher intakes of total fat, PUFA, SFA, LA and ALA, but lower in the highest quintile of TFA intake. BMI was significantly lower in the highest vs. lowest quintile of total PUFA (0.3 ± 0.13 kg/m^2^, *p* \< 0.001), LA (0.3 ± 0.13 kg/m^2^, *p* = 0.020) and ALA (0.6 ± 0.13 kg/m^2^, *p* \< 0.001). Conversely, BMI was significantly higher in the highest quintiles of total fat and SFA. Mean physical activity (expressed as METs·min/week) was significantly higher in the highest quintile of MUFA, PUFA, ALA and ω-3 FA intakes, but lower in the highest quintile of SFA and TFA intakes. Statistical significant differences in education level were also found between quintile groups of total fat, MUFA, SFA, TFA, LA, and ω-3 FA intake. Statistical significant differences in smoking habits were also found between quintile groups of PUFA, SFA, TFA, ALA, and ω-3 FA.

The nutrient intake and food consumption of the participants as per quintiles of total and several subtypes of dietary fat were also assessed ([Table 2](#nutrients-11-01493-t002){ref-type="table"} and [Table 3](#nutrients-11-01493-t003){ref-type="table"}). Participants in the highest quintile of total dietary fat intake had significantly lower intakes of energy, carbohydrates, protein, and fiber, but higher intakes of all subtypes of fat (PUFA, MUFA, SFA, TFA, LA, ALA, and ω-3 FA). Participants in the highest quintiles of PUFA, LA, and ALA intake had lower TFA and cholesterol intakes but higher fiber intake (except for ALA quintiles). Fiber intake was also higher in participants in the highest quintile of ω-3 FA intake. Participants in the highest quintile of ω-3 FA and SFA intake had significantly higher intake of protein and cholesterol. Cholesterol intake was also higher in participants in the highest quintile of TFA. FQI increased significantly with increasing quintiles of total and all subtypes of dietary intake except for SFA and TFA.

Consumption of olive oil, nuts, total fish, and total meat increased significantly with increasing quintiles of total dietary fat intake, whereas consumption of fruits, vegetables, legumes, total cereals, dairy products, cookies, and alcohol decreased. Similar results were obtained when MUFA quintiles were assessed. In contrast, participants in the highest quintile of PUFA intake had higher consumption of vegetables and legumes but lower total meat consumption. Participants in the highest quintile of ω-3 FA intake had higher consumption of fruits, vegetables, legumes, and total meat; and highest quintile of ALA intake had higher consumption of vegetables but lower of fruits, legumes, total cereals and olive oil, as well as meat. Otherwise, participants in the highest quintile of SFA intake had lower consumption of fruits, vegetables, legumes, nuts, total fish, total cereals, and dairy products, but higher consumption of total meat and cookies. Highest quintile of TFA intake was also associated with higher consumption of total cereals, dairy products, total meat, cookies and alcohol but lower consumption of fruits and vegetables. Overall, participants in the highest quintile of total and all subtypes of dietary fat intake had a significantly higher MedDiet score, except for SFA and TFA intake.

Prevalence of hyperglycemia was significantly higher in the highest quintiles of total and all subtypes of dietary fat intake except for TFA and ALA intake. Prevalence of low HDL-c was also higher in participants with the highest quintile of total fat, PUFA and LA intake but lower in the highest quintiles of ω-3 FA, MUFA, SFA, and TFA intake; and abdominal obesity prevalence was higher in participants with the highest quintile of ALA intake. Contrarily, the prevalence of hypertriglyceridemia was lower in participants with high ω-3 FA intake. Hypertension prevalence did not differ significantly according to intake of any type of fat.

Multivariate adjusted Odds Ratios (ORs) for components of the MetS across quintiles of total dietary fat intake and several subtypes of dietary fat intake are presented in [Table 4](#nutrients-11-01493-t004){ref-type="table"}. After adjustment for potential confounders (i.e., age, sex, BMI, smoking habit, education, energy, and alcohol intake, adherence to the MedDiet and physical activity), the OR of hyperglycemia were 1.2--1.6 times higher from the fourth-fifth quintile (Q4--Q5) of total fat and MUFA intakes compared with the first quintile; the OR of hyperglycemia were 1.3--1.6 times higher from the third-fifth quintile (Q3--Q5) of SFA intake compared with the first quintile. However, the OR for ω-3 FA intake was 1.3 times higher only for the fifth quintile (Q5) compared with the first quintile. The OR of low HDL-c was also 1.2 times higher for the fifth quintile of LA compared with the first quintile. Contrarily, the OR of hypertriglyceridemia were 0.7--0.8 times lower from the third quintiles (Q3--Q5) of SFA intake and the OR for ω-3 FA intake was 0.7 times lower only for the fifth quintile compared with the first quintiles.

4. Discussion {#sec4-nutrients-11-01493}
=============

In this cross-sectional study we evaluated the association of total dietary fat and specific subtypes of dietary fat intake with the components of MetS in a Mediterranean population at high cardiovascular risk. The most important finding of the present study is a significant increase in the risk of hyperglycemia among participants in the upper quintiles of total dietary fat, SFA, MUFA, and ω-3 FA intake, a significant increase in the risk of low HDL-c levels among participants in the upper quintile of LA, and a significant decrease in the risk of hypertriglyceridemia among participants in the upper quintiles of SFA and ω-3 FA intakes.

Controversial results in relation to hyperglycemia and dietary fat intake associations have been observed in the literature. Our results are in accordance with those reporting that fat intake is positively associated with the prevalence of impaired fasting glucose \[[@B34-nutrients-11-01493],[@B35-nutrients-11-01493]\] and lately diagnosed and undiagnosed T2DM \[[@B34-nutrients-11-01493],[@B36-nutrients-11-01493],[@B37-nutrients-11-01493]\]. Nevertheless, several studies did not highlight any association between total fat intake and TD2M risk \[[@B38-nutrients-11-01493],[@B39-nutrients-11-01493],[@B40-nutrients-11-01493],[@B41-nutrients-11-01493],[@B42-nutrients-11-01493]\]. Therefore, dietary fats could affect insulin resistance or risk of diabetes through several mechanisms. In the state of insulin resistance, lipogenesis is inhibited and lipolysis is exalted in adipocytes, which increases concentrations of circulating fatty acids. Consequently, typical dyslipidaemia is characterized by elevated TG, lowered HDL-C, and small and dense LDL-C particles, established as a risk factor for CVD, and associated with hyperinsulinaemia \[[@B43-nutrients-11-01493]\]. In the vascular-metabolic Clinica Universidad de Navarra (VM-CUN) cohort, the prediction ability of triglyceride-glucose index (TyG index) and fasting plasma glucose was compared to predict incident T2DM and reported that its predictive ability is better than that of the Homeostatic Model Assessment for Insulin Resistance (HOMA-IR) \[[@B44-nutrients-11-01493]\]. Moreover, the higher level of TyG index was significantly associated with an increased risk of incident T2DM \[[@B45-nutrients-11-01493]\] and developing CVD \[[@B46-nutrients-11-01493]\].

On the other hand, in our study high SFA intake and hyperglycemia were also positively associated. A recent systematic review also pointed out positive associations between SFA intake and insulin sensitivity in observational studies, but any association between SFA intake and incidence of T2DM in prospective studies \[[@B47-nutrients-11-01493]\]. Another systematic review and meta-analysis of observational studies did not found any association between SFA and T2DM \[[@B48-nutrients-11-01493]\]. The (Lipids, Genes and Metabolic Syndrome Study (LIPGENE study) showed that MetS subjects responded differently to dietary fat modification according to their homeostasis model assessment-insulin resistance (HOMA-IR) status. Insulin-resistant MetS subjects with the highest HOMA-IR decreased fasting insulin and HOMA-IR concentrations after consumption of a high MUFA (HMUFA) diet and high-complex carbohydrate (LFHCC) diet supplemented with long-chain n-3 PUFA diet, and these decreases in the two markers were significantly lower than with the high SFA (HSFA) diet. Conversely, fasting insulin and HOMA-IR concentrations increased in the least insulin-resistant group after consumption of a high SFA (HSFA) diet \[[@B49-nutrients-11-01493]\].

Our results also show a significant increase in the prevalence of hyperglycemia with increasing MUFA and ω-3 FA intake. However, our results could be attributed to lower consumption of fruits, vegetables, legumes, fiber, and a higher meat intake among participants with the highest MUFA intake but contrary to the participants with the lowest ω-3 FA intake. A recent systematic review and meta-analysis of randomized controlled feeding trials showed beneficial effects of MUFA and PUFA on glucose-insulin homeostasis. Replacement of 5% dietary energy from carbohydrates or SFA with 5% dietary energy from either MUFA or PUFA lowered glycosylated hemoglobin A1C (HbA1c) and HOMA-IR. Replacement of 5% dietary energy from carbohydrates, SFA, or MUFA with PUFA also showed beneficial effects on insulin secretion ability \[[@B50-nutrients-11-01493]\]. Therefore, the modification of an individual dietary pattern to regularly include foods rich in MUFA and PUFA, such as the MedDiet, can benefit individuals with MetS and hyperglycemia or TD2M \[[@B51-nutrients-11-01493]\].

We also found that the OR for hypertriglyceridemia was lower in the upper quintiles of SFA intake (Q3--Q5). Contrarily to our results, a positive association of SFA intake with serum TG has been found in the literature \[[@B52-nutrients-11-01493],[@B53-nutrients-11-01493],[@B54-nutrients-11-01493],[@B55-nutrients-11-01493]\]. Otherwise, a previous systematic review pointed out that the replacement of 1% dietary energy from SFA with MUFA or PUFA lowered TG levels \[[@B56-nutrients-11-01493]\]. However, our results could be attributed to the synergistic effect of high olive oil consumption (a healthy source of MUFA) among participants with the highest SFA intake. However, other studies have not found significant association between MUFA and MetS components, such as hypertriglyceridemia \[[@B52-nutrients-11-01493],[@B57-nutrients-11-01493]\].

The present study also showed a significant increase in risk of hypertriglyceridemia in the upper quintile of ω-3 FA intake. Accordingly, some studies have shown that the intake of ω-3 FA, eicosapentaenoic acid (EPA), and docosahexaenoic acid (DHA), be effective in reducing plasma TG concentrations \[[@B47-nutrients-11-01493],[@B52-nutrients-11-01493],[@B58-nutrients-11-01493],[@B59-nutrients-11-01493]\]. Other authors have also reported that low fat diets enriched with PUFA or replaced by healthy sources of fats (fish, avocado, nuts, broccoli, thistle, olives, linseed, and canola oil, etc.) or healthy sources of carbohydrates (whole grains, legumes, vegetables, and fruits) also decreased TG levels \[[@B49-nutrients-11-01493],[@B60-nutrients-11-01493],[@B61-nutrients-11-01493],[@B62-nutrients-11-01493],[@B63-nutrients-11-01493],[@B64-nutrients-11-01493],[@B65-nutrients-11-01493]\].

A previous systematic review of clinical trials found that some studies have observed that various conjugated linoleic acid (CLA) isomers, administered as supplements or CLA-enriched products, decreases HDL-c \[[@B66-nutrients-11-01493]\]. Another systematic review pointed out an inverse association between LA intake and CHD risk \[[@B67-nutrients-11-01493]\]. Recently, Yanai et al. \[[@B68-nutrients-11-01493]\] pointed out that TFA is significantly associated with reduction of HDL-c and coronary risks, whereas MUFA, plant sterols and stanols intake (except policosanol) may not affect HDL-c. Conversely, fish oils consumption, especially DHA consumption, may be favorably associated with HDL metabolism \[[@B68-nutrients-11-01493]\]. In our study, LA intake but not TFA was significantly associated with low HDL-c levels.

It is also noting that no association between TFA intake and components of MetS was observed in our population; perhaps it is due to the intake of this type of fat being low in the elderly Mediterranean population, who consume low amounts of processed food \[[@B69-nutrients-11-01493]\]. However, the consumption of TFA has been identified as an important and modifiable risk factor for CHD \[[@B70-nutrients-11-01493]\]. Emerging data suggest that TFA is associated with all causes of mortality, total CHD, and CHD mortality, probably because of higher levels of intake of industrial TFA (products of partial hydrogenation of vegetable oils) than ruminant TFA (meats and dairy products of cows, sheep, and goats) \[[@B48-nutrients-11-01493]\].

Lately, abdominal obesity and HTN are not significantly associated with dietary fat intake, although these results could be attributed to the high prevalence of both MetS components in our population. However, another study showed a significant rise in the risk of abdominal obesity (OR 1.61, CI 1.23--2.13) and HTN (OR 1.39, CI 1.06--1.81) with increasing fat intake \[[@B35-nutrients-11-01493]\]. Moreover, findings from the Food4Me study showed a strong association between fat intake (total fat, MUFA, and SFA) and obesity risk \[[@B71-nutrients-11-01493]\], which in agreement with two Cochrane meta-analyses \[[@B70-nutrients-11-01493],[@B72-nutrients-11-01493]\] comparing the weight loss effects of a low fat diet with usual diet showed an effect size of −1.5 kg and was mirrored by reductions in BMI (−0.5 kg/m^2^) and WC (−0.3 cm). Otherwise, a high-quality, moderately high-fat eating pattern (especially unsaturated fatty acids: PUFA and MUFA) like the MedDiet may have beneficial effects on BW and obesity \[[@B73-nutrients-11-01493]\]. A recent meta-analysis also provided evidence that high MUFA diets, as well as the Dietary Approaches to Stop Hypertension (DASH) and Mediterranean diets, and supplementation with ω-3 FA (EPA+DHA) effectively lowers blood pressure \[[@B47-nutrients-11-01493]\]. No evidence of harmful effects of reducing SFA intakes on blood pressure has been observed in the literature \[[@B70-nutrients-11-01493]\].

Our results may help to highlight the fact that dietary recommendations should focus not on lowering the total fat content of the diet but rather on specific types of fats and carbohydrates and, more importantly, on specific foods and overall dietary patterns \[[@B9-nutrients-11-01493]\] for individuals at high CVD risk.

5. Strengths and Limitations {#sec5-nutrients-11-01493}
============================

Our study also has various strengths. The large study sample is highly representative of Spanish older adults with MetS (*n* = 6560), and the use of a standardized protocol reduces information bias about food intake, socioeconomic and lifestyles variables. Some methodological limitations should be acknowledged. First, the cross-sectional study nature; thus, causal inferences cannot be drawn. Second, the FFQ, the source of information to assess dietary fat intake, could overestimate the intake of certain food groups even having been validated. Third, we excluded participants with energy intake out of predefined ranges, to avoid information bias \[[@B15-nutrients-11-01493]\]. Previously, in the PREDIMED study, 827 participants who had extreme values for total energy intake or any micronutrient intake out of the predefined values were also excluded in the nutritional adequacy analysis \[[@B15-nutrients-11-01493]\]. Moreover, the present findings cannot be extrapolated to other population groups given that our study participants are senior adults with overweight/obesity and MetS. Although there have been controversies regarding the criteria of MetS, the harmonizing worldwide criteria have been agreed on by international academic societies \[[@B15-nutrients-11-01493]\]. However, some professional societies have pointed out the limitations of MetS as clinical and epidemiologic too \[[@B74-nutrients-11-01493],[@B75-nutrients-11-01493],[@B76-nutrients-11-01493]\]. Finally, the overestimation of the prevalence ratios derived from the OR when logistic regression is applied.

6. Conclusions {#sec6-nutrients-11-01493}
==============

These data suggest a potential different role of types of dietary fat on the MetS components of individuals at high cardiovascular risk. Our main findings suggest that the intake of dietary fat was associated with a higher risk of hyperglycemia. It is likely that the effects of dietary fat intake on cardiometabolic syndrome will be influenced by the combination of nutrients of the food consumed. Therefore, the type of dietary fat should be considered for future dietary recommendations to decrease risk of MetS at a population level.
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nutrients-11-01493-t001_Table 1

###### 

Lifestyle characteristics and Metabolic Syndrome components according to total dietary fat and specific types of fat (g/day).

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                            Total Fat        MUFAs               PUFAs                SFAs                                                                                                                           
  ----------------------------------------- ---------------- ------------------- -------------------- ---------------- ----------------- --------- ---------------- ------------------ --------- ---------------- ------------------ ---------
  Participants, *n*                         1294             1291                                     1312             1312                        1312             1312                         1312             1312               

  Age, years                                65.1 ± 5.0       64.7 ± 4.9          0.164                65.1 ± 5.0       64.8 ± 4.8        0.088     64.7 ±5.0 \*     65.3 ± 4.9 \*      0.016     65.2 ± 5.0 \*    64.5 ± 5.0 \*      \<0.001

  Women, %                                  43.4             48.5                \<0.001              45.0             48.8              0.094     40.5             49.2               \<0.001   42.5             46.7               \<0.001

  BMI, kg/m^2^                              32.4 ± 3.4       32.8 ± 3.5 ^NS^     0.005                32.4 ± 3.4       32.7 ± 3.6        0.226     32.6 ± 3.4 \*    32.3 ± 3.4 \*      \<0.001   32.3 ± 3.3 \*    32.8 ±3.5 \*       \<0.001

  Smoking habit, %                                                                                                                                                                                                                   

  Current                                   11.6             12.0                0.820                11.1             12.0              0.446     14.1             11.5               0.002     11.2             12.5               0.021

  Former                                    44.0             44.6                42.2                 44.9             47.1              41.7      46.7             45.2                                                             

  Never                                     44.5             43.4                46.7                 43.1             38.8              46.8      42.1             42.3                                                             

  Education, %                                                                                                                                                                                                                       

  Primary                                   52.3             42.6                \<0.001              52.8             44.5              0.001     46.2             48.7               0.268     50.3             40.3               \<0.001

  Secondary                                 28.3             30.3                27.7                 29.6             30.6              28.2      27.8             34.7                                                             

  University or graduate                    19.4             27.1                19.5                 25.9             23.2              23.1      21.9             25.0                                                             

  Total physical activity, *n* †            1213             1225                                     1226             1240                        1225             1251                         1235             1248               

  Total physical activity,\                 2394 ± 2024      2440 ± 1876         0.912                2396 ± 1965 \*   2486 ± 1883 \*    0.027     2322 ± 2019      2529 ± 1875 ^NS^   0.025     2628 ± 2042 \*   2281 ± 1918 \*     \<0.001
  MET·min/week †                                                                                                                                                                                                                     

  Males                                     2796 ± 2268      2632 ± 2029         0.233                2745 ± 2177      2744 ± 2029       0.146     2674 ± 2231      2838 ± 2088        0.366     3053 ± 2256 \*   2572 ± 2163 \*     0.001

  Females                                   1868 ± 1500 \*   2233 ± 1672 \*      0.004                1970 ± 1569 \*   2213 ± 1673 \*    0.005     1799 ± 1513 \*   2205 ± 1559 \*     \<0.001   2039 ± 1518      1950 ± 1531        0.458

  MetS components, %                                                                                                                                                                                                                 

  High blood pressure                       93.0             91.7                0.328                92.5             91.3              0.300     92.8             92.0               0.724     92.5             91.3               0.495

  Hyperglycaemia                            73.9             80.3                \<0.001              74.0             80.0              \<0.001   73.3             75.6               0.014     73.2             78.3               0.032

  Hypertriglyceridemia                      58.7             56.6                0.139                57.0             56.0              0.889     56.8             55.2               0.111     57.9             53.4               0.120

  Low HDL-cholesterol                       38.7             44.4                0.004                40.4             44.7              0.171     40.9             46.3               0.015     40.2             42.1               0.068

  Abdominal obesity                         95.2             96.7                0.180                95.4             96.6              0.317     95.6             96.6               0.657     95.5             96.4               0.380

  Males                                     92.0             94.3                0.387                92.2             94.0              0.386     93.1             94.2               0.704     92.6             93.8               0.503

  Females                                   99.5             99.4                0.944                99.3             99.4              0.453     99.2             99.2               0.543     99.5             99.3               0.990

                                            ***Trans* FA**   **Linoleic acid**   **Linolenic acid**   **ω-3 FA**                                                                                                                     

  Participants, *n*                         1312             1312                                     1312             1312                        1312             1312                         1312             1312               

  Age, years                                65.8 ± 4.7 \*    64.0 ± 5.1 \*       \<0.001              64.6 ± 5.0 \*    65.4 ± 4.9 \*     0.001     63.9 ± 5.0 \*    65.6 ± 4.8 \*      \<0.001   65.1 ± 5.0       65.1 ± 4.8         0.345

  Women, *n* (%)                            60.9             37.6                \<0.001              40.2             48.2              \<0.001   29.9             56.6               \<0.001   47.6             51.2               0.217

  BMI, kg/m^2^                              32.3 ± 3.4       32.6 ± 3.5          0.074                32.6 ± 3.4       32.3 ± 3.3 ^NS^   0.020     32.7 ± 3.4 \*    32.1 ± 3.3 \*      \<0.001   32.7 ± 3.4       32,5 ± 3.4         0.387

  Smoking habit, *n* (%)                                                                                                                                                                                                             

  Current                                   8.9              14.0                \<0.001              14.0             12.2              0.007     16.7             9.5                \<0.001   14.4             10.3               0.003

  Former                                    39.7             47.0                47.1                 41.8             49.6              39.4      42.4             45.1                                                             

  Never                                     51.4             39.0                39.0                 46.0             33.8              51.1      43.2             44.6                                                             

  Education, *n* (%)                                                                                                                                                                                                                 

  Primary                                   57.0             41.3                \<0.001              44.1             50.5              0.003     46.6             50.1               0.286     54.2             47.2               \<0.001

  Secondary                                 24.6             31.6                30.8                 28.1             29.9              27.6      27.4             27.8                                                             

  University or graduate                    18.4             27.1                25.2                 21.4             23.5              22.3      18.3             25.0                                                             

  Total physical activity, *n* †            1248             1230                                     1229             1249                        1216             1251                         1237             1253               

  Total physical activity, MET·min/week †   2572 ± 1924      2373 ± 1977         0.075                2445 ± 2098      2499 ± 1884       0.130     2454 ± 2099 \*   2621 ± 1961 \*     0.002     2227 ± 1952 \*   2673 ± 2038 \*     \<0.001

  Males                                     3107 ± 2208 \*   2580 ± 2168\*       \<0.001              2801 ± 2332      2852 ± 2095       0.491     2695 ± 2241 \*   3080 ± 2230 \*     0.015     2657 ± 2168      2983 ± 2341 ^NS^   0.048

  Females                                   2225 ± 1624 \*   2027 ± 1550 \*      0.006                1908 ± 1539      2114 ± 1534       0.191     1852 ± 1541 \*   2262 ± 1636 \*     \<0.001   1744 ± 1541 \*   2372 ± 1639 \*     \<0.001

  MetS components, *n* (%)                                                                                                                                                                                                           

  High blood pressure                       91.9             92.3                0.108                92.9             92.0              0.313     92.9             91.6               0.566     91.8             91.5               0.068

  Hyperglycaemia                            76.2             75.2                0.232                73.4             75.2              0.047     74.1             75.8               0.373     74.0             79.0               0.020

  Hypertriglyceridemia                      55.2             55.6                0.611                55.6             56.4              0.847     57.2             53.2               0.186     59.1             50.8               \<0.001

  Low HDL-cholesterol                       43.5             42.2                0.863                39.9             47.0              \<0.001   41.5             44.7               0.586     45.8             41.1               0.147

  Abdominal obesity                         95.9             95.7                0.360                95.6             96.3              0.850     94.4             97.0               0.009     95.8             97.1               0.179

  Males                                     90.6             93.7                0.170                93.1             93.5              0.948     92.2             94.0               0.414     92.6             94.7               0.338

  Females                                   99.2             99.2                0.587                99.2             99.2              0.479     99.7             99.2               0.343     99.4             99.4               0.210
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: BMI, body mass index; FA, fatty acids; HDL-cholesterol, high density lipoprotein cholesterol; MetS, Metabolic Syndrome; MET, metabolic equivalent of task; MUFAs monounsaturated fatty acids; PUFAs, polyunsaturated fatty acids; SFAs, saturated fatty acids. All values are means ± SDs unless otherwise indicated. All quartiles were included in theanalysis. Pearson's chi-square test was used for categorical variables, and 1-factor ANOVA was used for continuous variables. \* *p* \< 0.05 for between-group changes, after adjustment for multiple comparisons with the Bonferroni method. ^NS^ No statistical significance after post hoc test. † Participants who not responded the physical activity questionnaires and participants reporting outliers for total physical activity expressed as MET·min/week (at 3 or more standard deviations from the mean) were excluded from the analysis (i.e., 154 men and 196 women).

nutrients-11-01493-t002_Table 2

###### 

Nutrient intake according to total dietary fat and specific types of fat (g/day).

                                        Total Fat        MUFAs               PUFAs                SFAs                                                                                                                  
  ------------------------------------- ---------------- ------------------- -------------------- --------------- --------------- --------- --------------- ---------------- --------- ---------------- --------------- ---------
  Participants, *n*                     1294             1291                                     1312            1312                      1312            1312                       1312             1312            
  Energy intake, kcal/day               2446 ± 579 \*    2432 ± 509 \*       \<0.001              2415 ± 594 \*   2417 ± 516 \*   \<0.001   2539 ± 534 \*   2498 ± 517 \*    \<0.001   2532 ± 533 \*    2456 ± 551 \*   \<0.001
  Carbohydrate intake, % total energy   48.6 ± 5.4 \*    33.3 ± 4.3 \*       \<0.001              48.0 ± 5.6 \*   34.1 ± 4.9 \*   \<0.001   45.7 ± 6.5 \*   37.7 ± 6.2 \*    \<0.001   46.3 ± 6.3 \*    36.0 ± 5.7 \*   \<0.001
  Protein intake, % total energy        16.7 ± 3.0 \*    15.9 ± 2.5 \*       \<0.001              17.0 ± 3.0 \*   15.7 ± 2.4 \*   \<0.001   16.3 ± 2.7 \*   16.2 ± 2.7 \*    \<0.001   15.9± 2.7 \*     16.7 ± 2.7 \*   \<0.001
  Fat intake, % total energy            30.5 ± 2.9 \*    48.5 ± 3.3 \*       \<0.001              31.4 ± 3.9 \*   47.6 ± 4.1 \*   \<0.001   33.7 ± 5.1 \*   43.7 ±5.9 \*     \<0.001   33.5 ± 5.1 \*    44.8 ± 5.5 \*   \<0.001
  PUFA, % total energy                  5.0 ± 1.3 \*     7.8 ± 2.0 \*        \<0.001              5.5 ± 1.9 \*    7.4 ± 1.6 \*    \<0.001   4.3 ± 0.5 \*    9.1 ± 1.5 \*     \<0.001   6.0 ± 1.8 \*     6.4 ± 1.8 \*    \<0.001
  MUFA, % total energy                  14.8 ± 2.2 \*    26.2 ± 3.5 \*       \<0.001              14.3 ± 1.8 \*   26.9 ± 2.9 \*   \<0.001   17.0 ± 3.2 \*   22.2 ± 5.0 \*    \<0.001   17.5 ± 4.1 \*    22.7 ± 4.4 \*   \<0.001
  SFA, % total energy                   8.2 ± 1.5 \*     11.7 ± 1.9 \*       \<0.001              8.7 ± 1.8 \*    11.0 ± 1.9 \*   \<0.001   9.6 ± 2.2 \*    10.0 ± 1.8 \*    \<0.001   7.5 ± 0.9 \*     12.8 ± 1.4 \*   \<0.001
  *Trans* FA, g/day                     0.52 ± 0.3 \*    0.71 ± 0.5 \*       \<0.001              0.57 ± 0.4 \*   0.63 ± 0.4 \*   \<0.001   0.66 ± 0.4 \*   0.59 ± 0.4 \*    \<0.001   0.39 ± 0.3 \*    0.94 ± 0.5 \*   \<0.001
  Linoleic acid, g/day                  11.1 ± 4.5 \*    17.4 ± 6.4 \*       \<0.001              12.0 ± 5.7 \*   16.3 ± 5.4 \*   \<0.001   9.8 ± 3.1 \*    20.8 ± 5.5 \*    \<0.001   13.7 ± 5.4 \*    14.3 ± 5.8 \*   \<0.001
  Linolenic acid, g/day                 1.2 ± 0.6 \*     1.8 ± 0.8 \*        \<0.001              1.3 ± 0.7 \*    1.7 ± 0.7 \*    \<0.001   1.1 ± 0.3 \*    2.3 ± 0.8 \*     \<0.001   1.4 ± 0.7 \*     1.6 ± 0.6 \*    \<0.001
  ω-3 FA, g/day                         1.48 ± 0.9 \*    1.65 ± 0.9 \*       \<0.001              1.52 ± 0.9 \*   1.61 ± 0.8 \*   0.001     1.39 ± 0.8 \*   1.72 ± 0.89 \*   \<0.001   1.59 ± 0.9       1.55 ± 0.8      0.360
  FQI, score                            2.4 ± 0.5 \*     3.0 ± 0.7 \*        \<0.001              2.29 ± 0.5 \*   3.15 ± 0.7 \*   \<0.001   2.26 ± 0.5 \*   3.16 ± 0.7 \*    \<0.001   3.12 ± 0.7 \*    2.24 ± 0.4 \*   \<0.001
  Cholesterol (mg/day)                  365 ± 113 \*     399 ± 119 \*        \<0.001              378 ± 122       383 ± 115       0.182     394 ± 134 \*    381 ± 111 \*     \<0.001   346 ± 106 \*     438 ± 125 \*    \<0.001
  Fibre intake (g/day)                  29 ± 10.0 \*     23.8 ± 7.7 \*       \<0.001              27.9 ± 9.2 \*   25.0 ± 8.4 \*   \<0.001   26.6 ± 9.0 \*   28.3 ± 9.1 \*    \<0.001   31.2 ± 10.3 \*   22.6 ± 7.2 \*   \<0.001
                                        ***Trans* FA**   **Linoleic acid**   **Linolenic acid**   **ω-3 FA**                                                                                                            
  Participants, *n*                     1312             1312                                     1312            1312                      1312            1312                       1312             1312            
  Energy intake, kcal/day               2001 ± 467 \*    2739 ± 522 \*       \<0.001              2541 ± 528 \*   2489 ± 518 \*   \<0.001   2894 ± 419 \*   2271 ± 517 \*    \<0.001   2176 ± 549 \*    2517 ± 520 \*   \<0.001
  Carbohydrate intake, % total energy   46.3 ± 6.3 \*    36.0 ± 5.7 \*       \<0.001              44.9 ± 6.7 \*   38.0 ± 6.2 \*   \<0.001   44.4 ± 6.5      38.0 ± 6.4       \<0.001   43.0 ± 7.2 \*    39.1 ± 6.3 \*   \<0.001
  Protein intake, % total energy        17.1 ± 3.2 \*    16.0 ± 2.5 \*       \<0.001              16.8 ± 3.0 \*   15.9 ± 2.5 \*   \<0.001   15.2 ± 2.2      17.2 ± 2.9       \<0.001   15.5 ± 2.8 \*    17.8 ± 2.6 \*   \<0.001
  Fat intake, % total energy            38.1 ± 7.2 \*    40.9 ± 6.0 \*       \<0.001              34.0 ± 5.4 \*   43.7 ± 5.9 \*   \<0.001   34.0 ± 5.4      43.7 ± 5.9       \<0.001   38.5 ± 7.0 \*    40.1 ± 6.2 \*   \<0.001
  PUFA, % total energy                  6.4 ± 2.0 \*     6.3 ± 1.7 \*        0.044                4.4 ± 0.6 \*    9.1 ± 1.6 \*    \<0.001   5.4 ± 1.5       8.5 ± 1.7        \<0.001   6.0 ± 2.0 \*     6.8 ± 1.8 \*    \<0.001
  MUFA, % total energy                  20.6 ± 5.3       20.6 ± 4.2          0.581                17.1 ± 3.3 \*   22.2 ± 5.0 \*   \<0.001   18.2 ± 3.8      21.8 ± 5.0       \<0.001   20.1 ± 4.9 \*    20.7 ± 4.5 \*   0.003
  SFA, % total energy                   7.5 ± 0.9 \*     12.8 ± 1.4 \*       \<0.001              9.7 ± 2.3 \*    10.0 ± 1.8 \*   \<0.001   9.4 ± 1.8       9.9 ± 2.1        \<0.001   9.8 ± 2.1        9.9 ± 1.9       0.168
  *Trans* FA, g/day                     0.18 ± 0.1 \*    1.18 ± 0.4 \*       \<0.001              0.65 ± 0.4 \*   0.62 ± 0.4 \*   \<0.001   0.70 ± 0.4 \*   0.52 ± 0.4 \*    \<0.001   0.57 ± 0.4 \*    0.58 ± 0.4 \*   0.015
  Linoleic acid, g/day                  11.4 ± 5.1 \*    16.1 ± 6.1 \*       \<0.001              9.6 ± 2.9 \*    20.9 ± 5.4 \*   \<0.001   14.2 ± 5.3 \*   17.5 ± 5.7 \*    \<0.001   12.5 ± 5.8 \*    14.4 ± 5.6 \*   \<0.001
  Linolenic acid, g/day                 1.3 ± 0.7 \*     1.7 ± 0.7 \*        \<0.001              1.1 ± 0.3 \*    2.2 ± 0.8 \*    \<0.001   1.2 ± 0.3 \*    2.3 ± 0.8 \*     \<0.001   1.2 ± 0.7 \*     1.7 ± 0.7 \*    \<0.001
  ω-3 FA, g/day                         1.54 ± 0.9 \*    1.56 ± 0.8 \*       0.170                1.62 ± 0.9 \*   1.58 ± 0.9 \*   0.009     1.56 ± 0.8 \*   1.69 ± 0.9 \*    \<0.001   0.63 ± 0.2 \*    2.92 ± 0.4 \*   \<0.001
  FQI, score                            3.25 ± 0.7 \*    2.29 ± 0.5 \*       \<0.001              2.25 ± 0.5 \*   3.14 ± 0.7 \*   \<0.001   2.51 ± 0.5 \*   3.08 ± 0.7 \*    \<0.001   2.67 ± 0.7 \*    2.78 ± 0.6 \*   \<0.001
  Cholesterol (mg/day)                  300 ± 90 \*      461 ± 124 \*        \<0.001              406 ± 135 \*    376 ± 111 \*    \<0.001   427 ± 140 \*    361 ± 106 \*     \<0.001   305 ± 100 \*     445 ± 116 \*    \<0.001
  Fibre intake (g/day)                  26.2 ± 9.0       25.8 ± 8.4          0.784                27.1 ± 9.1 \*   27.6 ± 9.1 \*   \<0.001   28.1 ± 9.0 \*   28.0 ± 9.2 \*    \<0.001   23.1 ± 8.2 \*    28.7 ± 9.1 \*   \<0.001

Abbreviations: FA, fatty acids; FQI, fat quality index; MUFAs, monounsaturated fatty acids; PUFAs, polyunsaturated fatty acids; SFAs, saturated fatty acids. All values are means ± SDs unless otherwise indicated. All quartiles were included in the analysis. Pearson's chi-square test was used for categorical variables, and 1-factor ANOVA was used for continuous variables. \* *p* \< 0.05 for between-group changes, after adjustment for multiple comparisons with the Bonferroni method.

nutrients-11-01493-t003_Table 3

###### 

Food consumption according to total dietary fat and specific types of fat (g/day).

                             Total Fat        MUFAs               PUFAs                SFAs                                                                                                                      
  -------------------------- ---------------- ------------------- -------------------- ---------------- ---------------- --------- ---------------- ---------------- --------- ---------------- ---------------- ---------
  Participants, *n*          1294             1291                                     1312             1312                       1312             1312                       1312             1312             
  Dietary items                                                                                                                                                                                                  
  Fruits, g/day              420 ± 259 \*     305 ± 170 \*        \<0.001              404 ± 239 \*     327 ± 183 \*     \<0.001   383 ± 238 \*     370 ± 205 \*     \<0.001   444 ± 258 \*     289 ± 172 \*     \<0.001
  Vegetables, g/day          333 ± 149 \*     310 ± 128 \*        \<0.001              331 ± 148 \*     320 ± 132 \*     0.001     319 ± 144 \*     340 ± 138 \*     \<0.001   356 ± 154 \*     292 ± 129 \*     \<0.001
  Legumes, g/day             22 ± 13 \*       19 ± 10 \*          \<0.001              22 ± 13 \*       20 ± 10 \*       \<0.001   20 ± 12 \*       21 ± 11 \*       0.004     23 ± 13 \*       19 ± 10 \*       \<0.001
  Olive oil, g/day           27 ± 13 \*       55 ± 14 \*          \<0.001              23 ± 10 \*       57 ± 13 \*       \<0.001   36 ± 15 \*       41 ± 19 \*       \<0.001   38 ± 16 \*       43 ± 18 \*       \<0.001
  Nuts, g/day                10 ± 12 \*       22 ± 23 \*          \<0.001              10 ± 12 \*       24 ± 24 \*       \<0.001   5 ± 6 \*         34 ± 23 \*       \<0.001   17 ± 20 \*       13 ± 15 \*       \<0.001
  Total fish, g/day          97 ± 49 \*       105 ± 47 \*         \<0.001              99 ± 50          103 ± 46 ^NS^    0.022     94 ± 46 \*       107 ± 48 \*      \<0.001   104 ± 50 \*      99 ± 47 \*       0.017
  Total cereals, g/day       203 ± 95 \*      110 ± 52 \*         \<0.001              190 ± 94 \*      118 ± 59 \*      \<0.001   196 ± 91 \*      138 ± 69 \*      \<0.001   208 ± 93 \*      118 ± 60 \*      \<0.001
  Dairy products, g/day      402 ± 226 \*     302 ± 177 \*        \<0.001              406 ± 220 \*     292 ± 175 \*     \<0.001   418 ± 223 \*     324 ± 197 \*     \<0.001   348 ± 226 \*     267 ± 202 \*     \<0.001
  Total meat, g/day          136 ± 57 \*      156 ± 61 \*         \<0.001              140 ± 59 \*      148 ± 58 \*      \<0.001   152 ± 59 \*      146 ± 59 \*      \<0.001   130 ± 52 \*      172 ± 62 \*      \<0.001
  Cookies, g/day             30 ± 35 \*       25 ± 27 \*          \<0.001              32 ± 35 \*       23 ± 25 \*       \<0.001   36 ± 39 \*       25 ± 27 \*       \<0.001   23 ± 27 \*       35 ± 35 \*       \<0.001
  Alcohol, g/day             15 ± 20 \*       8 ± 11 \*           \<0.001              13 ± 18 \*       9 ± 12 \*        \<0.001   16 ± 20 \*       9 ± 13 \*        \<0.001   16 ± 20 \*       9 ± 12 \*        \<0.001
  17-item MedDiet Q, score   8.27 ± 2.62 \*   8.56 ± 2.69 \*      0.005                8.19 ± 2.67 \*   8.88 ± 2.61 \*   \<0.001   7.68 ± 2.57 \*   9.07 ± 2.73 \*   \<0.001   9.09 ± 2.67 \*   7.65 ± 2.54 \*   \<0.001
                             ***Trans* FA**   **Linoleic acid**   **Linolenic acid**   **ω-3 FA**                                                                                                                
  Participants, *n*          1312             1312                                     1312             1312                       1312             1312                       1312             1312             
  Dietary items                                                                                                                                                                                                  
  Fruits, g/day              379 ± 207 \*     334 ± 198 \*        \<0.001              390 ± 239 \*     365 ± 206 \*     \<0.001   383 ± 237 \*     378 ± 216 \*     \<0.001   321 ± 209 \*     392 ± 229 \*     \<0.001
  Vegetables, g/day          332 ± 137 \*     309 ± 134 \*        \<0.001              335 ± 150 \*     330 ± 137 \*     0.001     326 ± 143 \*     347 ± 139 \*     \<0.001   269 ± 125 \*     377 ± 145 \*     \<0.001
  Legumes, g/day             20 ± 12          21 ± 11             0.730                21 ± 12          21 ± 11          0.061     22 ± 12 \*       21 ± 11 \*       \<0.001   19 ± 11 \*       23 ± 12 \*       \<0.001
  Olive oil, g/day           39 ± 17          40 ± 18             0.154                35 ± 15 \*       42 ± 19 \*       \<0.001   42 ± 17 \*       39 ± 17 \*       \<0.001   37 ± 18 \*       42 ± 17 \*       \<0.001
  Nuts, g/day                15 ± 18          15 ± 17             0.293                5 ± 7 \*         32 ± 24 \*       \<0.001   9 ± 12 \*        33 ± 20 \*       \<0.001   11 ± 16 \*       18 ± 19 \*       \<0.001
  Total fish, g/day          100 ± 49         101 ± 49            0.243                105 ± 51 \*      101 ± 47 \*      0.002     102 ± 51 \*      105 ± 46 \*      \<0.001   50 ± 23 \*       162 ± 37 \*      \<0.001
  Total cereals, g/day       135 ± 74 \*      163 ± 80 \*         \<0.001              191 ± 90 \*      138 ± 70 \*      \<0.001   213 ± 88 \*      128 ± 68 \*      \<0.001   145 ± 81         152 ± 75         0.140
  Dairy products, g/day      322 ± 213 \*     388 ± 204 \*        \<0.001              411 ± 225 \*     326 ± 196 \*     \<0.001   391 ± 222 \*     329 ± 199 \*     \<0.001   353 ± 214        349 ± 202        0.082
  Total meat, g/day          112 ± 44 \*      170 ± 63 \*         \<0.001              156 ± 59 \*      144 ± 58 \*      \<0.001   161 ± 61 \*      141 ± 57 \*      \<0.001   128 ± 58 \*      156 ± 60 \*      \<0.001
  Cookies, g/day             16 ± 24 \*       43 ± 38 \*          \<0.001              33 ± 38 \*       27 ± 29 \*       \<0.001   41 ± 41 \*       21 ± 25 \*       \<0.001   27 ± 32 \*       24 ± 27 \*       0.001
  Alcohol, g/day             7 ± 12 \*        13 ± 16 \*          \<0.001              16 ± 19 \*       9 ± 12 \*        \<0.001   19 ± 21 \*       7 ± 11 \*        \<0.001   10 ± 15 \*       11 ± 14 \*       0.030
  17-item MedDiet Q, score   9.82 ± 2.49 \*   7.50 ± 2.59 \*      \<0.001              7.97 ± 2.58 \*   8.86 ± 2.76 \*   \<0.001   7.67 ± 2.62 \*   9.49 ± 2.59 \*   \<0.001   7.64 ± 2.57 \*   9.46 ± 2.59 \*   \<0.001

Abbreviations: FA, fatty acids; MedDiet Q, Mediterranean Diet Questionnaire; MUFAs, monounsaturated fatty acids; PUFAs, polyunsaturated fatty acids; SFAs, saturated fatty acids. All values are means ± SDs unless otherwise indicated. All quartiles were included in the analysis. Pearson's chi-square test was used for categorical variables, and 1-factor ANOVA was used for continuous variables. \* *p* \< 0.05 for between-group changes, after adjustment for multiple comparisons with the Bonferroni method. ^NS^ No statistical significance after post hoc test.
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###### 

Association between total dietary fat and specific types of fat with the Metabolic Syndrome components (as dichotomous variables).

                              Quintiles     *p* Value                                                                                   
  --------------------------- ------------- ------------------- ----------------------- ----------------------- ----------------------- ---------
  **[Total fat]{.ul}**                                                                                                                  
  High blood pressure         1.00 (ref.)   0.99 (0.73, 1.35)   0.81 (0.61, 1.10)       0.96 (0.71, 1.30)       0.94 (0.69, 1.27)       0.615
  Hyperglycemia               1.00 (ref.)   0.94 (0.78, 1.12)   1.13 (0,94, 1.36)       **1.23 (1.02, 1.48)**   **1.55 (1.28, 1.88)**   \<0.001
  Hypertriglyceridemia        1.00 (ref.)   0.81 (0.69, 0.95)   0.88 (0.74, 1.03)       0.87 (0.74, 1.02)       0.90 (0.76, 1.06)       0.153
  Low HDL-c                   1.00 (ref.)   1.06 (0.90, 1.25)   1.19 (1.01, 1.40)       1.20 (1.02, 1.42)       1.14 (0.96, 1.34)       0.133
  Abdominal obesity           1.00 (ref.)   1.19 (0.81, 1.75)   1.33 (0.90, 1.98)       1.60 (1.06, 2.43)       1.75 (1.15, 2.68)       0.065
  **[MUFAs]{.ul}**                                                                                                                      
  High blood pressure         1.00 (ref.)   1.17 (0.86, 1.59)   0.99 (0.73, 1.33)       0.87 (0.65, 1.17)       0.97 (0.72, 1.31)       0.429
  Hyperglycemia               1.00 (ref.)   0.97 (0.81, 1.16)   0.98 (0.81, 1.17)       **1.26 (1.04, 1.52)**   **1.45 (1.19, 1.75)**   \<0.001
  Hypertriglyceridemia        1.00 (ref.)   0.93 (0.79, 1.09)   0.91 (0.78, 1.07)       0.99 (0.84, 1.16)       0.98 (0.83, 1.15)       0.741
  Low HDL-c                   1.00 (ref.)   1.07 (0.91, 1.26)   1.10 (0.94, 1.30)       1.18 (1.00, 1.38)       1.14 (0.97, 1.34)       0.359
  Abdominal obesity           1.00 (ref.)   1.12 (0.76, 1.66)   1.08 (0.73, 1.60)       1.58 (1.04, 2.42)       1.54 (1.01, 3.34)       0.111
  **[PUFAs]{.ul}**                                                                                                                      
  High blood pressure         1.00 (ref.)   0.94 (0.69, 1.28)   0.89 (0.65, 1.20)       0.87 (0.64, 1.17)       0.93 (0.69, 1.27)       0.902
  Hyperglycemia               1.00 (ref.)   1.02 (0.85, 1.23)   1.23 (1.02, 1.48)       1.23 (1.02, 1.49)       1.10 (0.91, 1.33)       0.084
  Hypertriglyceridemia        1.00 (ref.)   1.10 (0.93, 1.29)   0.92 (0.78, 1.08)       1.12 (0.95, 1.33)       1.05 (0.89, 1.24)       0.105
  Low HDL-c                   1.00 (ref.)   0.96 (0.81, 1.13)   0.96 (0.82, 1.14)       1.11 (0.94, 1.31)       1.12 (0.95, 1.32)       0.160
  Abdominal obesity           1.00 (ref.)   1.05 (0.70, 1.58)   1.13 (0.74, 1.71)       1.06 (0.71, 1.60)       1.31 (0.86, 2.00)       0.771
  **[SFAs]{.ul}**                                                                                                                       
  High blood pressure         1.00 (ref.)   0.86 (0.64, 1.15)   1.10 (0.81, 1.50)       1.08 (0.80, 1.47)       0.95 (0.70, 1.28)       0.432
  Hyperglycemia               1.00 (ref.)   1.17 (0.97, 1.41)   **1.25 (1.04, 1.51)**   **1.35 (1.12, 1.63)**   **1.58 (1.31, 1.92)**   \<0.001
  Hypertriglyceridemia        1.00 (ref.)   0.96 (0.81, 1.13)   **0.83 (0.71, 0.98)**   **0.85 (0.72, 1.00)**   **0.74 (0.63, 0.87)**   0.003
  Low HDL-c                   1.00 (ref.)   1.12 (0.95, 1.32)   1.00 (0.84, 1.18)       1.12 (0.94, 1.32)       0.94 (0.79, 1.11)       0.137
  Abdominal obesity           1.00 (ref.)   1.07 (0.72, 1.61)   1.40 (0.91, 2.16)       1.02 (0.68, 1.53)       1.33 (0.87, 2.02)       0.404
  **[*Trans* FA]{.ul}**                                                                                                                 
  High blood pressure         1.00 (ref.)   0.97 (0.72, 1.30)   1.27 (0.92, 1.74)       0.87 (0.64, 1.18)       1.14 (0.81, 1.60)       0.114
  Hyperglycemia               1.00 (ref.)   0.94 (0.78, 1.14)   1.17 (0.96, 1.43)       1.03 (0.84, 1.26)       1.12 (0.90, 1.38)       0.191
  Hypertriglyceridemia        1.00 (ref.)   0.93 (0.79, 1.09)   0.93 (0.79, 1.10)       0.95 (0.80, 1.13)       0.81 (0.68, 0.98)       0.246
  Low HDL-c                   1.00 (ref.)   0.99 (0.84, 1.16)   1.02 (0.87, 1.21)       0.92 (0.78, 1.10)       0.89 (0.74, 1.07)       0.489
  Abdominal obesity           1.00 (ref.)   1.68 (1.07, 2.64)   1.28 (0.84, 1.95)       1.34 (0.87, 2.07)       1.44 (0.91, 2.30)       0.256
  **[Linoleic acid]{.ul}**                                                                                                              
  High blood pressure         1.00 (ref.)   0.98 (0.72, 1.34)   0.77 (0.57, 1.04)       0.93 (0.68, 1.26)       0.91 (0.67, 1.23)       0.423
  Hyperglycemia               1.00 (ref.)   1.08 (0.91, 1.32)   1.17 (0.97, 1.41)       1.24 (1.03, 1.50)       1.08 (0.90, 1.30)       0.222
  Hypertriglyceridemia        1.00 (ref.)   1.00 (0.85, 1.18)   1.05 (0.89, 1.24)       1.14 (0.97, 1.35)       1.12 (0.95, 1.32)       0.354
  Low HDL-c                   1.00 (ref.)   0.90 (0.76, 1.06)   1.08 (0.91, 1.27)       1.14 (0.97, 1.34)       **1.18 (1.00, 1.39)**   0.009
  Abdominal obesity           1.00 (ref.)   1.14 (0.75, 1.73)   1.11 (0.74, 1.69)       1.12 (0.75, 1.69)       1.19 (0.79, 1.79)       0.939
  **[Linolenic acid]{.ul}**                                                                                                             
  High blood pressure         1.00 (ref.)   0.83 (0.61, 1.13)   0.82 (0.59, 1.15)       0.99 (0.69, 1.40)       0.82 (0.59, 1.14)       0.488
  Hyperglycemia               1.00 (ref.)   1.05 (0.86, 1.27)   1.17 (0.95, 1.44)       1.08 (0.87, 1.34)       1.03 (0.84, 1.26)       0.614
  Hypertriglyceridemia        1.00 (ref.)   1.10 (0.92, 1.30)   1.12 (0.94, 1.35)       1.09 (0.91, 1.32)       1.05 (0.88, 1.26)       0.744
  Low HDL-c                   1.00 (ref.)   1.00 (0.84, 1.19)   0.97 (0.80, 1.16)       0.94 (0.78, 1.14)       1.04 (0.87, 1.25)       0.822
  Abdominal obesity           1.00 (ref.)   1.54 (1.02, 2.33)   1.36 (0.87, 2.12)       1.20 (0.77, 1.89)       1.53 (0.98, 2.41)       0.219
  **[ω-3 FA]{.ul}**                                                                                                                     
  High blood pressure         1.00 (ref.)   0.97 (0.73, 1.30)   1.45 (1.06, 1.99)       0.93 (0.69, 1.25)       1.03 (0.76, 1.40)       0.048
  Hyperglycemia               1.00 (ref.)   1.13 (0.94, 1.36)   1.02 (0.85, 1.23)       1.08 (0.89, 1.30)       **1.33 (1.09, 1.62)**   0.036
  Hypertriglyceridemia        1.00 (ref.)   0.86 (0.73, 1.02)   0.97 (0.82, 1.14)       0.91 (0.77, 1.08)       **0.77 (0.65, 0.91)**   0.016
  Low HDL-c                   1.00 (ref.)   0.91 (0.77, 1.07)   0.86 (0.73, 1.01)       0.97 (0.82, 1.14)       0.84 (0.71, 1.00)       0.175
  Abdominal obesity           1.00 (ref.)   1.22 (0.81, 1.86)   1.05 (0.70, 1.57)       0.93 (0.62, 1.40)       1.50 (0.95, 2.38)       0.237

Abbreviations: CI, confidence interval; HDL-c, high density lipoprotein cholesterol; OR, odds ratio; ref., reference. Values are expressed as *n* (%) and OR (95% CI). Logistic regression analysis comparing the presence of Metabolic Syndrome and its components (independent variables) between quintiles of total dietary fat and specific types (dependent variable). Logistic regression analysis after adjustment for sex, age (continuous variable), body mass index (continuous variable), smoking habit (categorized variable), education (categorized variable), energy intake (continuous variable), alcohol intake (continuous variable), adherence to the Mediterranean Diet (continuous variable) and physical activity (continuous variable, expressed as MET·min/week). ^2^Participants who not responded the physical activity questionnaires and participants reporting outliers for total physical activity expressed as MET·min/week (at 3 or more standard deviations from the mean) were excluded from the analysis (i.e., 154 men and 196 women).
